This A3AR agonist, also called Namodenoson or CF 102, has been evaluated in clinical trials by Can‐Fite BioPharma Ltd. (Israel) for different tumor types and recently obtained permission from the US Food and Drug Administration (FDA) for a phase II clinical trial to treat metabolic dysfunction‐associated steatohepatitis (MASH) [12, 13]. This evidence concerns the gene ADORA3 and neoplasm.